Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 20/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29486335 | 0.75 | NR2E1 (0.51) | — | |
| SCHEMBL14584257 | 0.70 | BRD3 (0.57) | — | |
| SCHEMBL4091350 | 0.70 | BRD3 (0.57) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL11084665 | 0.70 | HTR2A (0.39) | SSTR3 | |
| SCHEMBL21309538 | 0.70 | CYP2D6 (0.47) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL11090267 | 0.69 | HTR7 (0.38) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3805259 | 0.69 | HTR2A (0.68) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL7088610 | 0.68 | BRD3 (0.67) | — | |
| SCHEMBL11081951 | 0.67 | ESR1 (0.40) | SSTR3KCNH2 | |
| SCHEMBL11084255 | 0.67 | SSTR3 (0.37) | SSTR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062251-A1 | Novel Compounds 002 | OPRL1, OPRK1, OPRM1 | SSTR3 845/4885KCNH2 445/4885CACNA1F 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.